Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1CNS 1

Conditions

Leukemia 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 271Specimen Handling 266pembrolizumab 233Cyclophosphamide 219Radiotherapy 208Nivolumab 169Cisplatin 165Biopsy 152Carboplatin 145Radiosurgery 131fludarabine 125Blood Specimen Collection 120Gemcitabine 113Paclitaxel 109Surveys and Questionnaires 108Standard of Care 106venetoclax 97Dexamethasone 95Bevacizumab 93Radiation 87Rituximab 83Capecitabine 81Cytarabine 80Oxaliplatin 77Drug Therapy 76Doxorubicin 75Ipilimumab 74durvalumab 73fludarabine phosphate 70atezolizumab 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Valacyclovir × 90 days × Clear all
NCT06914479 2026-05-27

Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors

University of Michigan Rogel Cancer Center

Phase 1 Recruiting
11 enrolled
CNS

Brain Neoplasms

NCT05536349 2026-04-30

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

M.D. Anderson Cancer Center

Phase 2 Recruiting
60 enrolled
Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡